A detailed history of Swiss National Bank transactions in 89bio, Inc. stock. As of the latest transaction made, Swiss National Bank holds 140,500 shares of ETNB stock, worth $1.08 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
140,500
Previous 140,500 -0.0%
Holding current value
$1.08 Million
Previous $1.13 Million 7.64%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 08, 2024

SELL
$7.31 - $10.9 $48,977 - $73,030
-6,700 Reduced 4.55%
140,500 $1.13 Million
Q1 2024

May 07, 2024

BUY
$8.13 - $13.77 $35,772 - $60,588
4,400 Added 3.08%
147,200 $1.71 Million
Q4 2023

Feb 06, 2024

BUY
$6.66 - $16.03 $204,462 - $492,121
30,700 Added 27.39%
142,800 $1.6 Million
Q3 2023

Nov 08, 2023

BUY
$15.06 - $19.41 $16,566 - $21,351
1,100 Added 0.99%
112,100 $1.73 Million
Q2 2023

Aug 09, 2023

BUY
$14.15 - $22.03 $1.57 Million - $2.45 Million
111,000 New
111,000 $2.1 Million

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $357M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track Swiss National Bank Portfolio

Follow Swiss National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.